$1.00
2.04% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Iterum Therapeutics Plc Stock price

$1.00
-0.12 10.71% 1M
-1.39 58.16% 6M
-0.77 43.50% YTD
-0.29 22.48% 1Y
-2.35 70.16% 3Y
-24.50 96.08% 5Y
-191.75 99.48% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.02 2.04%
ISIN
IE00BF3W0Q35
Symbol
ITRM
Sector
Industry

Key metrics

Market capitalization $40.00m
Enterprise Value $59.37m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-16.24m
Free Cash Flow (TTM) Free Cash Flow $-16.75m
Cash position $12.65m
EPS (TTM) EPS $-0.66
P/E forward negative
P/S forward 8.57
EV/Sales forward 12.72
Short interest 3.28%
Show more

Is Iterum Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Iterum Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Iterum Therapeutics Plc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Iterum Therapeutics Plc forecast:

Buy
100%

Financial data from Iterum Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.60 0.60
-
-
-0.60 -0.60
-
-
- Selling and Administrative Expenses 8.58 8.58
13% 13%
-
- Research and Development Expense 7.07 7.07
81% 81%
-
-16 -16
64% 64%
-
- Depreciation and Amortization 0.63 0.63
52% 52%
-
EBIT (Operating Income) EBIT -16 -16
64% 64%
-
Net Profit -23 -23
37% 37%
-

In millions USD.

Don't miss a Thing! We will send you all news about Iterum Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iterum Therapeutics Plc Stock News

Neutral
GlobeNewsWire
13 days ago
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory...
Neutral
Seeking Alpha
19 days ago
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Matthew Keller - H.C. Wainwright Operator Hello, everyone, and thank you for joining the Iterum Therapeutics plc First Quarter 2025 Ear...
Neutral
GlobeNewsWire
19 days ago
--Preparing for Potential Launch of ORLYNVAH TM by Q4 2025-- - -Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both com...
More Iterum Therapeutics Plc News

Company Profile

Iterum Therapeutics Plc is a pharmaceutical company which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Corey Fishman
Employees 14
Founded 2015
Website www.iterumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today